In This Article:
NEW YORK, NY / ACCESSWIRE / June 22, 2020 / Jakubowitz Law announces that securities fraud class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies who purchased shares within the class periods listed below. Shareholders interested in representing the class of wronged shareholders have until the lead plaintiff deadline to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. For more details and to speak with our firm without cost or obligation, follow the links below.
Hallmark Financial Services, Inc. (HALL)
CONTACT JAKUBOWITZ ABOUT HALL:
https://claimyourloss.com/securities/hallmark-financial-services-inc-loss-submission-form/?id=7444&from=1
Class Period : March 5, 2019 - March 17, 2020
Lead Plaintiff Deadline : July 6, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked effective internal controls over accounting and financial reporting related to reserves for unpaid losses; (2) the Company improperly accounted for reserve for unpaid losses and loss adjustment expenses related to its Binding Primary Commercial Auto business; (3) as a result, Hallmark Financial would be forced to report a $63.8 million loss development for prior underwriting years; (4) as a result, Hallmark Financial would exit from its Binding Primary Commercial Auto business; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
CytomX Therapeutics, Inc. (CTMX)
CONTACT JAKUBOWITZ ABOUT CTMX:
https://claimyourloss.com/securities/cytomx-therapeutics-inc-loss-submission-form/?id=7444&from=1
Class Period : May 17, 2018 - May 13, 2020
Lead Plaintiff Deadline : July 20, 2020
The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) CytomX had downplayed issues with CX-072's efficacy observed in the PROCLAIM-CX-072 clinical program; (ii) CytomX had similarly downplayed issues with CX-2009's efficacy and safety observed in the PROCLAIM-CX-2009 clinical program; and (iii) as a result, the Company's public statements were materially false and misleading at all relevant times.
Sorrento Therapeutics, Inc. (SRNE)
CONTACT JAKUBOWITZ ABOUT SRNE:
https://claimyourloss.com/securities/sorrento-therapeutics-inc-loss-submission-form/?id=7444&from=1
Class Period : May 15, 2020 - May 22, 2020
Lead Plaintiff Deadline : July 27, 2020